|Calculated MW||25 kDa (236 aa, 28-240 aa + His Tag), confirmed by MALDI-TOF.|
|Other Names||Insulin-like growth factor-binding protein 6, IBP6|
|Sequence||MGSSHHHHHH SSGLVPRGSH MGSRCPGCGQ GVQAGCPGGC VEEEDGGSPA EGCAEAEGCL RREGQECGVY TPNCAPGLQC HPPKDDEAPL RALLLGRGRC LPARAPAVAE ENPKESKPQA GTARPQDVNR RDQQRNPGTS TTPSQPNSAG VQDTEMGPCR RHLDSVLQQL QTEVYRGAQT LYVPNCDHRG FYRKRQCRSS QGQRRGPCWC VDRMGKSLPG SPDGNGSSSC PTGSSG|
|Storage||-80°C; 0.5 mg/ml in 20 mM Tris-HCl buffer (pH 8.0) containing 0.15 M NaCl, 1 mM DTT and 20% glycerol.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IGFBP6 contains 1 IGFBP N-terminal domain and 1 thyroglobulin type-1 domain. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Recombinant human IGFPB6 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques.
Kiefer M.C.,et al.J. Biol. Chem. 266:9043-9049(1991).
Ehrenborg E.,et al.Mamm. Genome 10:376-380(1999).
Shimasaki S.,et al.Mol. Endocrinol. 5:938-948(1991).
Zapf J.,et al.J. Biol. Chem. 265:14892-14898(1990).
Roghani M.,et al.FEBS Lett. 255:253-258(1989).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.